Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beiyun Chen

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Clinical Nuclear Medicine|March 7, 2012
The use of molecular breast imaging to assess response in women undergoing neoadjuvant therapy for breast cancer: a pilot studyDietlind L Wahner-Roedler, Judy C Boughey, Carrie B Hruska, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 16, 2005
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization studyJinru Shia, David S Klimstra, Allan R Li, et al.
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
American Journal of Clinical Pathology|May 4, 2021
Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization ResultsKatherine B Geiersbach, Daniel R Sill, Kristina M Del Rosario, et al.
The American Journal of Surgical Pathology|September 10, 2019
Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the BreastBeth T Harrison, Elizabeth Fowler, Gregor Krings, et al.
Journal of Surgical Oncology|April 19, 2017
Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsyBrittany L Murphy, Alexandra B Gonzalez, Amy L Conners, et al.
Journal of the National Cancer Institute|December 6, 2011
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteriaEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
The Oncologist|April 21, 2022
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)Kostandinos Sideras, David W Hillman, Karthik Giridhar, et al.
Breast Cancer Research and Treatment|June 7, 2020
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancerRoberto A Leon-Ferre, Edith A Perez, David W Hillman, et al.
Ultrasound in Medicine & Biology|April 4, 2024
Long-Term Ultrasound Twinkling Detectability and Safety of a Polymethyl Methacrylate Soft Tissue Marker Compared to Conventional Breast Biopsy Markers-A Preclinical Study in a Porcine ModelChristine U Lee, Matthew W Urban, Gina K Hesley, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Clinical Nuclear Medicine|March 7, 2012
The use of molecular breast imaging to assess response in women undergoing neoadjuvant therapy for breast cancer: a pilot studyDietlind L Wahner-Roedler, Judy C Boughey, Carrie B Hruska, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 16, 2005
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization studyJinru Shia, David S Klimstra, Allan R Li, et al.
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
American Journal of Clinical Pathology|May 4, 2021
Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization ResultsKatherine B Geiersbach, Daniel R Sill, Kristina M Del Rosario, et al.
The American Journal of Surgical Pathology|September 10, 2019
Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the BreastBeth T Harrison, Elizabeth Fowler, Gregor Krings, et al.
Journal of Surgical Oncology|April 19, 2017
Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsyBrittany L Murphy, Alexandra B Gonzalez, Amy L Conners, et al.
Journal of the National Cancer Institute|December 6, 2011
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteriaEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
The Oncologist|April 21, 2022
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)Kostandinos Sideras, David W Hillman, Karthik Giridhar, et al.
Breast Cancer Research and Treatment|June 7, 2020
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancerRoberto A Leon-Ferre, Edith A Perez, David W Hillman, et al.
Ultrasound in Medicine & Biology|April 4, 2024
Long-Term Ultrasound Twinkling Detectability and Safety of a Polymethyl Methacrylate Soft Tissue Marker Compared to Conventional Breast Biopsy Markers-A Preclinical Study in a Porcine ModelChristine U Lee, Matthew W Urban, Gina K Hesley, et al.
Pageof 7